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Abstract
(6) SKF83959, like many other arylbenzazepines, elicits powerful neuroprotection in vitro and in vivo. The neuroprotective
action of the compound was found to partially depend on its D1-like dopamine receptor agonistic activity. The precise
mechanism for the (6) SKF83959-mediated neuroprotection remains elusive. We report here that (6) SKF83959 is a potent
blocker for delayed rectifier K
+ channel. (6) SKF83959 inhibited the delayed rectifier K
+ current (IK) dose-dependently in rat
hippocampal neurons. The IC50 value for inhibition of IK was 41.962.3 mM (Hill coefficient=1.8160.13, n=6), whereas that
for inhibition of IA was 307.9638.5 mM (Hill coefficient=1.3760.08, n=6). Thus, (6) SKF83959 is 7.3-fold more potent in
suppressing IK than IA. Moreover, the inhibition of IK by (6) SKF83959 was voltage-dependent and not related to dopamine
receptors. The rapidly onset of inhibition and recovery suggests that the inhibition resulted from a direct interaction of (6)
SKF83959 with the K
+ channel. The intracellular application of (6) SKF83959 had no effects of on IK, indicating that the
compound most likely acts at the outer mouth of the pore of K
+ channel. We also tested the enantiomers of (6) SKF83959,
R-(+) SKF83959 (MCL-201), and S-(2) SKF83959 (MCL-202), as well as SKF38393; all these compounds inhibited IK. However,
(6) SKF83959, at either 0.1 or 1 mM, exhibited the strongest inhibition on the currents among all tested drug. The present
findings not only revealed a new potent blocker of IK , but also provided a novel mechanism for the neuroprotective action
of arylbenzazepines such as (6) SKF83959.
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Introduction
Atypical D1 receptor agonist (6) SKF83959, (6) 3-methyl-6-
chloro-7,8-hydroxy-1-(3-methylphenyl)-2,3,4,5-tetrahydro-1H-3-
benzazepine (Fig. 1), possesses a unique pharmacological property.
(6) SKF83959 does not stimulate cAMP formation in brain tissues
but activates the phosphatidylinositol (PI)-linked pathway via a D1-
like dopamine receptors (D1DAR) [1–5], although it produces D1
agonist-mediated behavioral responses in animals [6]. This
compound was shown to have anti-parkinsonian effect in an
experimental primate model as well as in the unilateral lesioned
rodent model for Parkinson’s disease [7–11]. Earlier studies with
(6) SKF83959 and its isomers, showed that such D1-like agonists
increase eye blinking in monkeys [12] and rats [13] and that the
magnitude of this effect may be related to agonistic efficacy.
Although there is a recent report by employing a different
approach depicting that (6) SKF83959 is able to stimulate native
brain tissues coupling to both Gs and Gq protein[14], the
antiparkinsonian mechanism of the agent, however, is known not
to relate to the cAMP pathway and may associate with the (6)
SKF83959-mediated PI-linked D1DAR activation [3,6,15–17]. In
agreement with a previous report in a model of primate
Parkinson’s disease, in which (6) SKF83959 not only reduced
the dyskinesias but also reduced the occurrence of motor
fluctuation and wearing-off dyskinesia [15], we have recently
demonstrated that chronic treatment of (6) SKF83959 resulted in
a significantly lower dyskinesia while eliciting its potent anti-
parkinsonian action in a model of 6-hydroxydopamine (6-OHDA)
unilaterally -lesioned rats. Moreover, a chronic administration of
(6) SKF83959 also significantly reduced levo-DOPA-induced
dyskinesias in PD rats [18]. The underlying mechanism for the
anti-dyskinesia action of (6) SKF83959 is believed to associate
with the drug’s powerful neuroprotective action [19]. Since it was
suggested that occurrence of motor fluctuation and wearing-off
dyskinesia are associated with anti-PD drug treatment-induced
further loss of dopaminergic neurons [20,21]. We recently
demonstrated that in both cultured neurons and in HEK293
cells, (6) SKF83959 inhibited GSK3b activity via a D1-like
receptor-dependent mechanism. However, blockage of D1-like
receptor activation which blunted SKF83959-mediated inhibition
on GSK3b,was found to attenuated partially the neuroprotective
PLoS ONE | www.plosone.org 1 June 2009 | Volume 4 | Issue 6 | e5811effect of (6) SKF83959 [19], indicating that D1-like receptor-
independent mechanism may be also involved in the neuropro-
tection of the drug.
Delayed rectifier K
+ channel plays an important role in
neuroprotection [22–24]. It has been proposed that decreased
intracellular K
+ due to activation of the K
+ channel contributes to
the neuroapoptosis induced by various insults such as Ab-amyloid
[22,25] and serum deprivation [23]. Tetraethylammonium (TEA),
a classical blocker of delayed rectifier K
+ channel, was found to
exert potent neuroprotective effects in vivo [26,27] and in vitro [23].
Considering the importance of delayed rectifier K
+ channel in
neuroprotection, we decided to explore the potential effect of (6)
SKF83959 on delayed rectifier K
+ channel as part of our efforts in
understanding the mechanism for the D1-receptor independent
neuroprotection of the drug. We here demonstrate that (6)
SKF83959 and related benzazepines are potent inhibitors of
delayed rectifier K
+ channel. The potency of (6) SKF83959 is
almost 25-fold higher than that of TEA. Our findings not only
revealed a new category of potent blockers of delayed rectifier K
+
channel but also provided a novel mechanism for the neuropro-
tective action of arylylbenzazepines analogs.
Materials and Methods
Materials
(6) SKF38393, (6)-SCH23390 hydrochloride, prazosin and
mesulergine were purchased from Sigma (St Louis, MO, USA)/
RBI (Natick, MA, USA). R-(+) SKF38393 (MCL-201) and S-(2)
SKF38393 (MCL-202) (Fig. 1) were synthesized in the Alcohol and
Drug Abuse Research Center at McLean Hospital (Belmont, MA,
USA). (6) SKF83959 was synthesized in the Synthetic Organic &
Medicinal Chemistry Laboratory, Shanghai Institute of Materia
Medica, Chinese Academy of Sciences. Other chemicals were
purchased from Sigma-Aldrich China Inc.
Preparation of dissociated hippocampal neurons
All procedures were in compliance with the Guidelines for the
Care and Use of Laboratory Animals (National Research Council,
People’s Republic of China, 1996). Dissociated hippocampal
neurons were prepared from newborn (5–9 day) Sprague-Dawley
rats as described previously [26]. Briefly, hippocampal slices
(500 mm) were cut in oxygenated ice-cold dissociation solution
consisted of the following (in mM): 82 Na2SO4,3 0K 2SO4,5
MgCl2, 10 HEPES, and 10 glucose, pH=7.3 adjusted with
NaOH. The slices were incubated in the dissociation solution
containing protease XXIII (3 g/L) at 32uC for 8 min, and then
placed in dissociation solution containing trypsin inhibitor type II-
S (1 g/L) and bovine serum albumin (1 g/L) at 24–25uC under an
oxygen atmosphere. Before recording, the CA1 region of several
slices was dissected, and triturated using a series of fire-polished
Pasteur pipettes with decreasing tip diameters. Dissociated
neurons were placed in a recording dish and superfused with an
external solution consisted of the following (in mM): 135 NaCl, 5
KCl, 1 CaCl2, 2 MgCl2, 10 HEPES, 10 glucose, 0.001
tetrodotoxin , pH=7.4 adjusted with NaOH..
Whole-cell voltage clamp recoding
Voltage-activated K
+ currents were recorded in large pyrami-
dal-shaped neurons using an Axopatch 200A amplifier (Axon
Instruments, USA) at 24–25uC [26]. Voltage protocols were
controlled by pClamp 9.0 software via a DigiData-1322A interface
(Axon Instruments, USA). Electrodes (a tip resistance of 3–5 MV)
were pulled from borosilicate grass pipettes (Sutter Instruments,
USA) and filled with a pipette solution consisted of the following
(in mM): 140 KCl, 2 MgCl2, 1 CaCl2, 10 HEPES, 10 EGTA
(pH 7.4 with KOH). The neurons were held at 250 mV. Unless
otherwise mentioned, the total K
+ current (Itotal) was elicited with
400-ms depolarizing steps to +40 mV following a 600-ms
hyperpolarizing prepulse to 2110 mV, delivered every 10 s.
The delayed rectifier K
+ current (IK) was elicited by using a similar
protocol, but a 50-ms interval at 250 mV was inserted after the
prepulse to inactivate the fast transient K
+ current (IA). IA is the
subtraction of IK from Itotal. Signals were filtered at 2–10 KHz and
sampled at frequencies of 10–40 KHz. Series resistance was
compensated by 75%–85%. Linear leak and residual capacitance
currents were subtracted online using a P/4 protocol.
Drug application
(6) SKF83959 and other drugs were dissolved in dimethylsulf-
oxide (DMSO) to prepare a stock solution of 10 mM and stored at
220uC. Before use, the stock solutions were diluted to desired
concentrations. For extracellular application, the drug-containing
external solution was delivered to the neuron using RSC-100 rapid
solution changer with a 9-tube head (BioLogic Co., France).
Figure 1. The structures of benzazepines.
doi:10.1371/journal.pone.0005811.g001
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on the voltage-activated K
+ currents (DMSO: 0.59860.11 nA;
control: 0.66060.095 nA, n=4; p.0.05). For intracellular
dialysis, (6) SKF83959 contained in the pipette solution was
diffused into the recorded neuron immediately after patch
membrane ruptured [29].
Data analysis
The peak amplitude of IA was measured, whereas the steady-
state amplitude of IK was measured at 300 ms after the initiation
of each voltage step. The decay time constants (t) of the currents
were obtained by fitting the decay time course with a mono-
exponential function. The concentrations of (6) SKF83959 to
yield 50% block of the K
+ currents (IC50) were obtained by fitting
normalized concentration–inhibition relationships to the equation:
I/I0=1/{1+([C]/IC50)
n}, where I0 and I are the current
amplitudes measured in control and in the presence of (6)
SKF83959, [C] is the concentration of (6) SKF83959 in the
external solution and n is the Hill coefficient. The ratio of
inhibition was calculated by using the equation: Inhibition=
(12I/I0)*100%, where I0 and I are the current amplitude in
control and in the presence of (6) SKF83959, respectively. For
analyzing the voltage-dependence of steady-state activation or
inactivation of IK, normalized conductance or current was plotted
against the membrane potential, and fitted to the Boltzmann
equation: Y=1/{1+exp[(V2V1/2)/k]}, where Y is the normalized
conductance or current, V is the test potential; V1/2 is the voltage
at half-maximal activation or inactivation of IK; k is the slope
factor. The time course of recovery of IK from inactivation was
fitted with a mono-exponential function: I/Imax=A*{1–exp[2Dt/
t]}, where Imax is the maximal current amplitude; I is the current
after a recovery period of Dt; t is the time constant; A is the
amplitude coefficient. Data are presented as mean6S.E.M.
Statistical significance was assessed using a Student’s t-test except
for the voltage dependence of inhibition of IK by (6) SKF83959
where one-way ANOVA test was used, and P,0.05 was
considered significant. All analyses were performed using the
software ‘‘GraphPad Prism 4’’ and ‘‘Excel 2000’’.
Results
Inhibition of voltage-activated K
+ currents by (6)
SKF83959 in hippoacampal neurons
Superfusion with (6) SKF83959 (10–1000 mM) inhibited both
IK and IA in concentration-dependent manner. However, the
compound preferentially inhibited IK to IA. As shown in Fig. 2A,
(6) SKF83959 (100 mM) markedly suppressed IK, whereas a
moderate reduction in the amplitude of IA was observed. The
inhibition of (6) SKF83959 on both K
+ currents had a rapid
onset, as it reached steady-state levels within 10 s. Moreover, the
K
+ currents were partially recovered upon washing out the
compound (Fig. 2B, 2C). The partial recovery may be because of
the run-down of the currents with recording, or due to the
incompletely drug washing- out.
Analyzing the concentration-inhibition relationships of (6)
SKF83959 on K
+ currents revealed that the IC50 value for
inhibition of IK was 41.962.3 mM (Hill coefficient=1.8160.13,
n=6), while that for inhibition of IA was 307.9638.5 mM (Hill
coefficient=1.3760.08, n=6) (Fig. 3A). Because (6) SKF83959 is
7.3-fold more potent in suppressing IK than IA, we thus focused on
characterizing the inhibition on IK.
We next examined whether the other substituted phenylbenza-
zepines such as R-(+) SKF83959 (MCL-201), S-(2) SKF83959
(MCL-202) and SKF38393 affect IK. The results are shown in
Fig. 3B. At the concentration of 100 mM, the inhibition of IK by
MCL-201, MCL-202 and SKF38393 was 36.764.1% (n=8),
9.761.7% (n=8) and 24.561.1% (n=7), respectively, whereas
(6) SKF83959 (100 mM) induced much greater inhibition on IK
(76.062.7%, n=6). At the concentration of 1 mM, the inhibition
of IK by MCL-201, MCL-202 and SKF38393 was 77.164.0%
(n=3), 56.162.7% (n=4) and 62.062.7% (n=5), respectively,
whereas (6) SKF83959 (1 mM) almost completely suppress the K
+
current (92.062.5%, n=3). Thus, (6) SKF83959 produced the
most potent inhibition of IK among the four substituted
benzazepines at tested concentrations.
Mechanisms underlying the inhibition of the delayed
rectifier K
+ current by (6) SKF83959
(6) SKF83959 is an atypical agonist of D1-like receptor. We first
examined whether the inhibition of IK by (6) SKF83959 was
mediated through activation of D1-like receptor. Pretreatment with
the D1 receptor antagonist SCH23390 did not significantly alter (6)
SKF83959-induced inhibition on IK (Fig. 4A). The inhibition of IK
by (6) SKF83959 (100 mM) in the presence of SCH23390 (20 mM)
was 60.162.7% (n=6), while that by (66) SKF83959 alone was
70.364.1% (n=7, P=0.074, t=1.97, df=11).
In addition to D1-like receptor, (6) SKF83959 also exhibits
moderate affinities to D2 receptors, a1-adrenoceptors and 5-HT2A
receptors [5]. However, neither the a1-adrenoceptors antagonist
prazosin,northe5-HTreceptorantagonistmesulergineaffected (6)
SKF83959-induced inhibition of IK (Fig. 4A). The inhibition of IK
by (6) SKF83959 (100 mM) in the presence of prazosin (10 mM) or
mesulergine (10 mM) was 76.662.1% (n=6) and 71.464.6%
(n=6), respectively, which was almost identical with that of (6)
SKF83959 alone treatment (70.364.1%, n=7, P=0.23, t=1.29,
df=11 vs. prazosin and P=0.86, t=0.18, df=11 vs. mesulergine).
Taken together, (6) SKF83959 is a potent blocker of the delayed
rectifier K
+ channel and the inhibitory action is independent of
either dopamine or serotonin receptors.
To determine the acting site of the agent on the K
+ channel, we
investigated the effect of intracellular dialysis of (6) SKF83959 on
IK. The concentration for intracellular dialysis was 300 mM, which
inhibited IK by nearly 90% and is close to the value of IC50 for IA,
when applied externally (Fig. 3A). Throughout the 10-min
recording period, the relative amplitudes of IK in the neurons
dialyzed with (6) SKF83959 were almost identical with that of in
the control group (Fig. 4B), so was the IK (data not shown). At the
end of 10-min recording, the relative amplitude of IK in control
and in the neurons dialyzed with (6) SKF83959 was 85.466.0%
(n=5) and 83.465.3% (n=7), respectively (P=0.81, t=0.25,
df=10). The results suggest that (6) SKF83959 acts at an
extracellular site of the delayed rectifier K
+ channel.
Voltage dependence of inhibition of the delayed rectifier
K
+ current by (6) SKF83959
The current-voltage (I/V) relationship of IK from a represen-
tative neuron in control and in the presence of (6) SKF83959
(100 mM) was plotted in Fig. 5A. (6) SKF83959 did not
significantly change the threshold for activation of IK, but caused
a remarkable downward shift of the I/V curve, and reduced its
amplitude over the entire period of activation. The inhibition of IK
by (6) SKF83959 seems to be greater at more depolarizing
potentials. Thus, we plotted the relative amplitudes of IK as a
function of the test potential. As shown in Fig. 5B, the inhibition of
IK by (6) SKF83959 steeply increased between 220 mV and
+20 mV. In the presence of (6) SKF83959, the relative currents in
steps to 220 mV and to +20 mV, respectively, were 43.566.1%
Arylbenzazepines Blocks Ik
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+20 mV and +80 mV the inhibition remained relatively constant.
The results demonstrated that the inhibition of IK by (6)
SKF83959 was voltage-dependent.
Effects of (6) SKF83959 on kinetic behaviors of the
delayed rectifier K
+ current
In addition to suppressing the amplitude of IK,( 6) SKF83959
(100 mM) markedly accelerated the decay of the current
(Fig. 6A&6B). The time course of the decay of the current trace
was fitted with a single exponential function. The decay time
constant (t) for IK was 145.9611.9 ms in control and
63.464.9 ms in the presence of 100 mM( 6) SKF83959 (n=7,
P=0.0002, t=6.42, df=12, vs. control) (Fig. 6C). Moreover, as
depicted in Fig. 6D, (6) SKF83959 suppressed the amplitude of
tail current, but did not cause a crossover of the tail current.
(6) SKF83959 (100 mM) elicited a marked hyperpolarizing shift
(nearly 20 mV) of the voltage dependence of steady-state
Figure 2. Inhibition of voltage-activated K
+ currents by (6) SKF83959 in rat hippocampal neurons. (A) Upper and lower are the
respective representative traces of the delayed rectifier K
+ current (IK) and fast transient K
+ current (IA) recorded prior to and during superfusion with
(6) SKF83959 (100 mM) and after 10 s of washout. The neuron was held at 250 mV. Upper inset shows the pulse protocol to elicit IK, whereas lower
inset shows the protocol to elicit the total K
+ current. IA is the subtraction of IK from the total K
+ current. (B) and (C) Time courses of the inhibition of IK
and IA by (6) SKF83959 (100 mM, n=5 for each). The bar denotes the surpufusion with SKF83959. A number of symbols in (B) and (C) have error bars
smaller than their size.
doi:10.1371/journal.pone.0005811.g002
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was changed from 21.762.6 mV to 222.263.1 mV (n=8,
P=0.0002, t=5.10, df=14), whereas the value of k for activation
was from 16.860.9 to 13.661.1, n=8, P=0.038, t=2.29,
df=14). (6) SKF83959 (100 mM) had no significant effect on its
steady-state inactivation (Fig. 7B). The value of V1/2 for
inactivation was nearly identical (285.861.3 mV in control
vs.286.363.9 mV in the presence of (6) SKF83959, n=8,
P=0.91, t=0.11, df=12). The value of k for inactivation has no
significant change (211.960.7 in control vs.216.764.8 in the
presence of (6) SKF83959, n=8, P=0.35, t=1.00, df=6). The
same treatment accelerated the recovery of IK from inactivation
(Fig. 7C). The time constant of recovery was found to reduce from
294.1630.4 ms to 107.7610.4 ms (n=6, P=0.0002, t=5.81,
df=10).
Discussion
(6) SKF83959 is a putative phosphatidylinositol (PI)-linked D1-
like receptor agonist [3,4]. The agent has been shown to possess
potent anti-parkinsonian effects in a variety of animal models for
Parkinson’s disease with less severedyskinesia and motor fluctuation
[6–8,15,18]. In the present study, we demonstrated for the first time
that (6) SKF83959 and other substituted phenylbenzazepines
inhibited the delayed rectifier K
+ current (IK) in rat hippocampal
neuronswiththe highest inhibition produced by (6) SKF83959. (6)
SKF83959 is nearly 25-fold more potent than tetraethylammonium
(TEA), a classical blocker of IK, which had an IC50 value of
1.0560.21 mM in the same preparations [28].
To elucidate the mechanisms underlying (6) SKF83959-
induced inhibition on IK, we found that the antagonists of D1,
Figure 3. Concentration-dependent inhibition of (6) SKF83959 on the voltage-activated K
+ currents. (A) Concentration-inhibition
curves of (6) SKF83959 on the delayed rectifier K
+ current (IK) and fast transient K
+ current (IA)(n=6 for IK and IA). A number of symbols have error bars
smaller than their size. (B) Comparison of the substituted phenylbenzazepine, MCL-201, MCL-202, SKF38393 and (6) SKF83959 in inhibition of IK.
doi:10.1371/journal.pone.0005811.g003
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SKF83959 (Fig. 3A), indicating that the inhibitory effect was a
receptor-independent event. Furthermore, the fast nature in the
onset of inhibition and recovery (Fig. 2B) implicates that the
inhibition results from a direct interaction of (6) SKF83959 with
the K
+ channel. Moreover, we found that intracellular application
of (6) SKF83959 had no effect on IK (Fig. 4B), suggesting that the
agent is most likely to act at the outer mouth of the pore of K
+
channel. In an effort to determine how (6) SKF83959 blocks the
K
+ channel. We demonstrated that the inhibition of IK by (6)
SKF83959 was voltage-dependent (Fig. 5). Furthermore, the agent
markedly accelerated the decay of IK in addition to suppressing its
amplitude (Fig. 6A), although lack of the crossover of tail current
(Fig. 6D). The results suggest that the agent preferentially binds to
the open state of the K
+ channel [30,31]. It is conceivable that (6)
SKF83959 acts as an open-channel blocker at the delayed rectifier
K
+ channel. (6) SKF83959 probably binds to the K
+ channel with
2:1 stoichometry (Hill coefficient=1.8160.13).
Accumulating evidence shows that loss of intracellular K
+ ions
through enhanced delayed rectifier K
+ channel (mainly Kv2.1
channel) mediates apoptosis of cortical neurons induced by a
variety of treatments, such as serum deprivation, exposure to
staurosporine or b–amyloid peptide fragment, etc. [23,25]. In 6-
hydroxydopamine -induced neurotoxicity, voltage-dependent po-
Figure 4. Block of the delayed rectifier K
+ channel by (6) SKF83959 in rat hippocampal neurons. (A) Inhibition of the delayed rectifier K
+
current (IK)b y( 6) SKF83959 (100 mM) in the presence of D1 receptor antagonist SCH23390 (20 mM, n=6), or a1-adrenoceptor antagonist prazosin
(10 mM, n=6), or 5-HT receptor antagonist mesulergine (10 mM, n=6). (B) Lacking effect of intracellular dialysis of (6) SKF83959 on IK (n=7). The
recording pipettes were filled with pipette solution containing (6) SKF83959 (300 mM). The downward arrow indicates the time when the patch
membrane was ruptured.
doi:10.1371/journal.pone.0005811.g004
Figure 5. Effects of (6) SKF83959 on the current-voltage relationships of the delayed rectifier K
+ current in rat hippocampal
neurons. (A) Current-voltage (I/V) curves of the delayed rectifier K
+ current (IK) obtained in a representative neuron in control and during superfusion
of (6) SKF83959 (100 mM). (B) Plot of the relative amplitudes of IK during superfusion of (6) SKF83959 (100 mM) as a function of the test potential.
Each symbol represents the mean6S.E.M. (n=7). The solid line is the linear fit, while the dashed line is the activation curve obtained in control
condition. *P,0.01 (one-way ANOVA test) versus the value at 220 mV.
doi:10.1371/journal.pone.0005811.g005
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+ current in rat hippocampal neurons. (A) Superimposed traces
of the delayed rectifier K
+ current (IK) in a representative neuron prior to and during superfusion with (6) SKF83959 (100 mM). (B) The trace with (6)
SKF83959 in (A) is scaled up. (C) Decay time constants of IK prior to and during superfusion with (6) SKF83959 (100 mM). n=7, *P,0.01 versus the
control. (D) Tail current traces evoked at 240 mV after a 500-ms depolarizing steps to +40 mV prior to and during superfusion with (6) SKF83959
(100 mM). Similar results were obtained in 3 neurons.
doi:10.1371/journal.pone.0005811.g006
Figure 7. Effects of (6) SKF83959 on the activation and steady-state inactivation of the delayed rectifier K
+ current in rat
hippocampal neurons. (A) Activation curves of the delayed rectifier K
+ current (IK) prior to and during superfusion with 100 mM( 6) SKF83959
(n=8). (B) Steady-state inactivation curves of IK prior to and during superfusion with 100 mM( 6) SKF83959 (n=8). (C) Time courses of recovery of IK
from inactivation prior to and during superfusion with 100 mM( 6) SKF83959 (n=6). For studying the activation, neurons were held at 250 mV,
currents were elicited with a series of 400-ms step from 280 mV to +80 mV in 10 mV increments following a 600-ms hyperpolarizing prepulse to
2110 mV and a 50-ms interval at 250 mV, delivered every 10 s. For studying the steady-state inactivation, neurons were held at 0 mV, currents were
elicited with a series of 600-ms prepulses at different hyperpolarizing potentials followed by a 50-ms interval at 250 mV and a 400-ms step to
+40 mV, then back to 0 mV, delivered every 10 s. For studying the time course of recovery from inactivation, neurons were held at 0 mV, currents
were elicited on return from hyperpolarizing prepulses of varying durations at 2110 mV to +40 mV, delivered every 10 s.
doi:10.1371/journal.pone.0005811.g007
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blockage of IK by TEA was shown to effectively against the
neurotoxicity and improve the neuronal viability. In other hand,
the neuroprotective effects of classical IK blocker TEA were also
demonstrated in animal models of transient focal ischemia [26,27].
Thus, the drug discovery targeted to specific K
+ channel has been
proposed as a potential therapeutic approach in treatment of
neurodegenerative diseases [33–35]. We recently demonstrated
that (6) SKF83959 protected rat cortical neurons against H2O2-
induced injury, which was partially mediated though a putative PI-
linked D1-like receptor-dependent mechanism via inhibition of
GSK3b pathway [19]. The finding of (6) SKF83959 and its
analogs as a potent blocker for the delayed rectifier K
+ channel in
the present study not only reveals a role of those compounds in the
modulation of K
+ channel, but also suggests a potential new
mechanism for the neuroprotection of phenylbenzazepine deriv-
atives. In the case of (6) SKF83959, how the neuroprotective
effects via blockage of the delayed rectifier K
+ channel contributes
to the observed attenuation in the development of dyskinesia and
reduction in the occurrence of motor fluctuation and wearing-off
dyskinesia in chronic (6) SKF83959-treated PD animals [7,18] are
worth of further study.
Author Contributions
Conceived and designed the experiments: GZJ GYH AZ XZ. Performed
the experiments: XC JZ. Analyzed the data: GYH AZ. Contributed
reagents/materials/analysis tools: JZ JLN AZ. Wrote the paper: JLN XZ.
References
1. Arnt J, Hyttel J, Sanchez C (1992) Partial and full dopamine D1 receptor
agonists in mice and rats: relation between behavioural effects and stimulation of
adenylate cyclase activity in vitro. Eur J Pharmacol 213: 259–267.
2. Cools AR, Lubbers L, van Oosten RV, Andringa G (2002) SKF 83959 is an
antagonist of dopamine D1-like receptors in the prefrontal cortex and nucleus
accumbens: a key to its antiparkinsonian effect in animals? Neuropharmacol 42:
237–245.
3. Jin L-Q, Goswami S, Cai G, Zhen XC, Friedman E (2003) SKF83959 selectively
regulates phosphatidylinositol-linked D1 dopamine receptors in rat brain.
J Neuroche 85: 378–386.
4. Panchalingam S, Undie AS (2001) SKF83959 exhibits biochemical agonism by
stimulating [35S]GTP[gamma]S binding and phosphoinositide hydrolysis in rat
and monkey brain. Neuropharmacol 40: 826–837.
5. Neumeyer JL, Kula NS, Bergman J, Baldessarini RJ (2003) Receptor affinities of
dopamine D1 receptor-selective novel phenylbenzazepines. Eur J Pharmacol
474: 137–140.
6. Deveney AM, Waddington JL (1995) Pharmacological characterization of
behavioural responses to SK&F83959 in relation to ‘D1-like’ dopamine
receptors not linked to adenylyl cyclase. Brit J Pharmacol 116: 2120–2126.
7. Gnanalingham KK, Erol DD, Hunter AJ, Smith LA, Jenner P, et al. (1995)
Differential anti-parkinsonian effects of benzazepine D1 dopamine agonists with
varying efficacies in the MPTP-treated common marmoset. Psychopharmacol
(Berl) 117: 275–286.
8. Gnanalingham K K, Hunter AJ, Jenner P, Marsden CD (1995) The differential
behavioural effects of benzazepine D1 dopamine agonists with varying efficacies,
co-administered with quinpirole in primate and rodent models of Parkinson’s
disease. Psychopharmacol (Berl) 117: 287–297.
9. Nutt JG, Carter JH, Lea ES, Woodward WR (1997) Motor fluctuations during
continuous levodopa infusions in patients with Parkinson’s disease. Move Disord
12: 285–292.
10. Waddington J, O’Tuathaigh C, O’Sullivan G, Tomiyama K, Koshikawa N, et
al. (2005) Phenotypic studies on dopamine receptor subtype and associated
signal transduction mutants: insights and challenges from 10 years at the
psychopharmacology–molecular biology interface. Psychopharmacol (Berl) 181:
611–638.
11. Wirtshafter D, Osborn CV (2005) The atypical dopamine D1 receptor agonist
SKF 83959 induces striatal Fos expression in rats. Eur J Pharmacol 528: 88–94.
12. Desai RI, Neumeyer JL, Paronis CA, Nguyen P, Berman J (2007) Behavioral
effects of R (+)a n dS( 2) enantiomers of the dopamine D1-like partial receptor
agonist. Eur J Pharmacol 558: 98–106.
13. Desai RI, Neumeyer JL, Bergman J, Paronis CA (2007) Pharmacological
characterization of the effects of dopamine D1 agonists on eye blinking in rats.
Behav Pharmacol 18: 745–754.
14. Mannoury la Cour C, Vidal S, Pasteau V, Cussac D, Millan MJ (2007)
Dopamine D1 receptor coupling to Gs/olf and Gq in rat striatum and cortex: A
scintillation proximity assay (SPA)/antibody-capture characterization of benza-
zepine agonists. Neuropharmacol 52: 1003–1014.
15. Andringa G, Stoof JC, Cools AR (1999) Sub-chronic administration of the
dopamine D1 antagonist SKF 83959 in bilaterally MPTP-treated rhesus
monkeys: stable therapeutic effects and wearing-off dyskinesia. Psychopharmacol
146: 328–334.
16. Clifford JJ, Tighe O, Croke DT, Kinsella A, Sibley DR, et al. (1999)
Conservation of behavioural topography to dopamine D1-like receptor agonists
in mutant mice lacking the D1A receptor implicates a D1-like receptor not
coupled to adenylyl cyclase. Neurosci 93: 1483–1489.
17. Zhen X, Goswami S, Friedman E (2005) The role of the phosphatidyinositol-
linked D1 dopamine receptor in the pharmacology of SKF83959. Pharmacol
Biochem Behav 80: 597–601.
18. Zhang H, Ma L, Wang F, Chen J, Zhen X (2007) Chronic SKF83959 induced
less severe dyskinesia and attenuated L-DOPA-induced dyskinesia in 6-OHDA-
lesioned rat model of Parkinson’s disease. Neuropharmacol 53: 125–133.
19. Yu Y, Wang JR, Sun PH, Guo Y, Zhang ZJ, et al. (2008) Neuroprotective effects
of atypical D1 receptor agonist SKF83959 are mediated via D1 receptor-
dependent inhibition of glycogen synthase kinase-3B; and a receptor-
independent anti-oxidative action. J Neruochem 104: 946–956.
20. Agnati LF, Leo G, Vergoni AV, Martinez E, Hockemeyer J, et al. (2004)
Neuroprotective effect of L-DOPA co-administered with the adenosine A2A
receptor agonist CGS 21680 in an animal model of Parkinson’s disease. Brain
Res Bull 64: 155–164.
21. Obeso JA, Rodriguez-Oroz M, Marin C, Alonso F, Zamarbide I, et al. (2004)
The origin of motor fluctuations in Parkinson’s disease: importance of
dopaminergic innervation and basal ganglia circuits. Neurology 62: S17–30.
22. Yu SP, Farhangrazi ZS, Ying HS, Yeh CH, Choi DW (1998) Enhancement of
outward potassium current may participate in b-amyloid peptide-induced
cortical neuronal death. Neurobiol Dis 5: 81–88.
23. Yu S-P, Yeh C-H, Sensi SL, Gwag BJ, Canzoniero LM, et al. (1997) Mediation
of neuronal apoptosis by enhancement of outward potassium current. Science
278: 114–117.
24. Pal S, Hartnett KA, Nerbonne JM, Levitan ES, Aizenman E (2003) Mediation
of neuronal apoptosis by Kv2.1-encoded potassium channels. J Neurosci 23:
4798–4802.
25. Franciosi S, Ryu JK, Choi HB, Radov L, Kim SU, et al. (2006) Broad-spectrum
effects of 4-aminopyridine to modulate amyloid b1-42-induced cell signaling and
functional responses in human microglia. J Neurosci 26: 11652–11664.
26. Huang H, Gao TM, Gong L-W, Zhuang Z-Y, Li X (2001) Potassium channel
blocker TEA prevents CA1 hippocampal injury following transient forebrain
ischemia in adult rats. Neurosci Lett 305: 83–86.
27. Wei L, Yu SP, Gottron F, Snider BJ, Zipfel, et al. (2003) Potassium channel
blockers attenuate hypoxia- and ishemia-induced neuronal death in vitro and in
vivo. Stroke 34: 1281–1286.
28. Song MK, Liu H, Jiang HL, Yue JM, Hu GY (2006) Electrophysiological
characterization of 14-benzoyltalatisamine, a selective blocker of the delayed
rectifier K+ channel found in virtual screening. Eur J Pharmacol 531: 47–53.
29. Hu GY, Biro Z, Hill RH, Grillner S (2002) Intracellular QX-314 causes
depression of membrane potential oscillations in lamprey spinal neurons during
fictive locomotion. J Neurophysiol 87: 2676–2683.
30. Delpon E, Valenzuela C, Gay P, Franqueza L, Snyders D J, et al. (1997) Block of
human cardiac Kv1.5 channels by loratadine: voltage-, time- and use-dependent
block at concentrations above therapeutic levels. Cardiovascul Res 35: 341–350.
31. Ahn H, Kim S, Jang H-J, Kim M-J, Rhie D-J, et al. (2007) Open channel block
of Kv1.3 by rosiglitazone and troglitazone: Kv1.3 as the pharmacological target
for rosiglitazone. Naunyn-Schmiedeberg’s Arch Pharmacol 374: 305–309.
32. Redman PT, Jefferson BS, Ziegler CB, Mortensen OV, Torres GE, et al. (2006)
A vital role for voltage-dependent potassium channels in dopamine transporter-
mediated 6-hydroxydopamine neurotoxicity. Neurosci 143: 1–6.
33. Shieh C-C, Coghlan M, Sullivan JP, Gopalakrishnan M (2000) Potassium
channels: molecular defects, diseases, and therapeutic opportunities. Pharmacol
Rev 52: 557–594.
34. Wickenden AD (2002) K+ channels as therapeutic drug targets. Pharmacol &
Therapeut 94: 157–182.
35. Zaks-Makhina E, Kim Y, Aizenman E, Levitan ES (2004) Novel Neuroprotec-
tive K+ Channel Inhibitor Identified by High-Throughput Screening in Yeast.
Mol Pharmacol 65: 214–219.
Arylbenzazepines Blocks Ik
PLoS ONE | www.plosone.org 8 June 2009 | Volume 4 | Issue 6 | e5811